Short answer
Fulgent Genetics, Inc. (FLGT) filed an 8-K current report with the SEC on November 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1), Item EX-99.2 (Exhibit EX-99.2). Fiscal quarter ended September 30, 2026 results announced by Fulgent Genetics.
Fulgent Genetics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Fiscal quarter ended September 30, 2026 results announced by Fulgent Genetics
- Press release furnished as Exhibit 99.1, containing the company’s financial results and management disclosures
Item 7.01 · Regulation FD Disclosure
- Updated investor presentation released November 5, 2026
- Presentation provides business updates and summaries for investors
- Exhibit 99.2 and Investor Relations website contain the substantive disclosure
Item EX-99.1 · Exhibit EX-99.1
- Q3 revenue $90.4M, up approximately 8% year over year, but GAAP gross margin fell to 35.3% from 42.2%
- GAAP loss widened to $13.2M, or $0.48 per share, from $6.6M, reflecting continued operating pressure
- Non-GAAP loss $2.4M, or $0.09 per share, versus $4.5M income, while adjusted EBITDA declined to a $7.5M loss
- Nine-month non-GAAP loss reached $29.6M, with non-GAAP operating margin deteriorating to -21.9% from -7.6%
- 2026 revenue guidance maintained at $330.0M-$340.0M, while expected non-GAAP loss improves to $46.0M-$50.0M and cash outlook to approximately $630.0M
Item EX-99.2 · Exhibit EX-99.2
- Investor presentation dated November 5, 2026 highlights diagnostics scale, oncology pipeline, and balance-sheet flexibility
- Q3 2026 revenue $90M, up 8% year over year, with LTM operating cash flow of $14M
- FY 2026 revenue guidance $330M-$340M, non-GAAP EPS $(1.65)-$(1.75), expected cash and investments approximately $630M
- FID-007 interim Phase 2 data: ORR 61.9%, median PFS 6.7 months, one-year overall survival 63.4%
- Clinical risk remains material: 80.4% experienced grade 3 or higher adverse events, including one treatment-related deathેણ
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Fulgent Genetics, Inc. 8-K filings
Get the next FLGT 8-K as it lands
Follow FLGT for push alerts, or ask the research agent what this filing means.